Date: 2017-10-03
Type of information: Construction of new premises
Compound: new production line at the manufacturing site of Bari
Company: Merck KGaA (Germany)
Therapeutic area:
Type agreement: construction of new premises
Action mechanism:
Disease:
Details:
- • On October 3, 2017, Merck KGaA announced that the gorup will invest € 35 million in a new production line for the aseptic filling of biotech medicines under isolator at its manufacturing site of Bari,
Italy. The announcement was made as part of an event celebrating the 25th anniversary of the site. The new production line is expected to be fully operational in 2022. It will be equipped with an isolator designed with the latest technologies available and with a high level of automation. The isolator technology represents best practice in aseptic filling which is a prerequisite to ensure the safety of injectable medicines. The new production line is intended to be used for the aseptic filling of the biotech medicines of Merck KGaA in the areas of multiple sclerosis, fertility and endocrinology with a capacity of 14 million units per year.
- In 2014, Merck KGaA, Darmstadt, Germany, already invested € 50 million at the Bari biotech-manufacturing site for a fully automated production line under isolator and automated warehouse. The site has been established in 1992 and currently employs 225 people. It is specialized in the fill & finish activities of biotech medicines in the areas of multiple sclerosis, fertility and endocrinology for more than 150 countries. The site is also involved in the manufacturing of some of the products under development of Merck KGaA.
Financial terms:
Latest news:
Is general: Yes
